

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Boflox flavour 80 mg tablets for dogs

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each tablet contains:

Active substance:

Marbofloxacin 80 mg

Excipients:

Qualitative composition of excipients and other constituents

Lactose monohydrate

Cellulose, powdered

Povidone

Crospovidone

Silica, colloidal anhydrous

Calcium behenate

Yeast

Beef flavour

Oblong beige tablets with brown speckles scored on both sides.
The tablets can be divided into halves.

3. CLINICAL INFORMATION

3.1 Target species

Dogs

3.2 Indications for use for each target species

Treatment of infections caused by strains of microorganisms susceptible to marbofloxacin. Please see section 4.2.

- skin and soft tissue infections (skinfold pyoderma, impetigo, folliculitis, furunculosis, cellulitis)
- urinary tract infections (UTI) associated or not with prostatitis or epididymitis
- respiratory tract infections.

3.3 Contraindications

Do not use in dogs aged less than 12 months, or less than 18 months for exceptionally large breeds of dogs, such as Great Dane, Briard, Bernese, Bouvier and Mastiff, with a longer growth period.

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

Do not use in cases of resistance against quinolones, since (almost) complete cross-resistance exists against other fluoroquinolones.

Not suitable for infections resulting from strict anaerobes, yeast or fungi.

Do not use in cats. For the treatment of this species, a divisible 20 mg tablet is available.

3.4 Special warnings

A low urinary pH could have an inhibitory effect on the activity of marbofloxacin. Pyoderma occurs mostly secondary to an underlying disease, thus, it is advisable to determine the underlying cause and treat the animal accordingly.

3.5 Special precautions for use

Special precautions for safe use in the target species:

The fluoroquinolones have been shown to induce erosion of articular cartilage in juvenile dogs and care should be taken to dose accurately especially in young animals.

The fluoroquinolones are also known for their potential neurological side effects. Cautious use is recommended in dogs and cats diagnosed as suffering from epilepsy.

Fluoroquinolones should be reserved for the treatment of clinical conditions which have responded poorly or are expected to respond poorly to other classes of antimicrobials. Use of the veterinary medicinal product should be based on susceptibility testing of the bacteria isolated from the animal. If this is not possible, therapy should be based on local (regional, farm level) epidemiological information about susceptibility of the target bacteria. Use of the veterinary medicinal product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to the fluoroquinolones and may reduce effectiveness of treatment with other quinolones due to the potential for cross-resistance. Official and local antimicrobial policies should be taken into account when the product is used.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

People with known hypersensitivity to (fluoro)quinolones should avoid contact with the veterinary medicinal product.

In case of accidental ingestion seek medical advice immediately and show the package leaflet or the label to the physician. Wash hands after use.

Special precautions for the protection of the environment:

Not applicable.

3.6 Adverse events

Dog:

Rare (1 to 10 animals / 10 000 animals treated):	Joint pain Neurological symptoms (ataxia, aggressiveness, convulsion, depression)
Undetermined frequency (cannot be estimated from the available data):	Allergic reaction ¹ (allergic skin reaction ²) Vomiting ³ , soft stool ³ , modification of thirst ³ Hyperactivity ^{2,3}

¹ Due to histamine release

² Temporary

³ Mild; cease spontaneously after treatment and do not necessitate cessation of treatment

At the therapeutic recommended dosage, no severe side-effects are to be expected in dogs.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

3.7 Use during pregnancy, lactation or lay

Pregnancy and lactation:

Studies in pregnant rats and rabbits showed no side effects on pregnancy. The safety of the veterinary medicinal product has not been established in dogs during pregnancy and lactation. Use only according to the benefit/risk assessment by the responsible veterinarian.

3.8 Interaction with other medicinal products and other forms of interaction

Fluoroquinolones are known to interact with orally administered cations (Aluminium, Calcium, Magnesium, Iron). In such cases, the bioavailability may be reduced.

Do not use in combination with tetracyclines, macrolides because of the potential antagonist effect.

When administered together with theophylline, the half-life and thus the plasma concentration of theophylline increases. Hence, the dose of theophylline should be reduced.

3.9 Administration routes and dosage

For oral administration.

The recommended dose rate is 2 mg/kg/d (1 tablet for 40 kg per day) in single daily administration. To ensure a correct dosage body weight should be determined as accurately as possible. Tablets may be divided along score lines to facilitate accurate dosing.

Duration of treatment:

In skin and soft tissue infections, treatment duration is at least 5 days. Depending on the course of the disease, it may be extended up to 40 days.

In urinary tract infections, treatment duration is at least 10 days. Depending on the course of the disease, it may be extended up to 28 days.

In respiratory infections, treatment duration is at least 7 days. Depending on the course of the disease, it may be extended up to 21 days.

3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)

Overdosage may cause cartilage damage in the joints and acute signs in the form of neurological disorders (e.g. salivation, streaming eyes, shivering, myoclonia, seizures), which should be treated symptomatically.

3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance

Not applicable.

3.12 Withdrawal periods

Not applicable

4. PHARMACOLOGICAL INFORMATION

4.1 ATCvet code:

QJ01MA93.

4.2 Pharmacodynamics

Marbofloxacin is a synthetic, bactericidal antimicrobial, belonging to the fluoroquinolone group which acts by inhibition of DNA gyrase and Topoisomerase IV. It is effective against a wide range of Gram positive bacteria and Gram negative bacteria. Efficacy was established in particular in:

- Skin and soft tissue infections caused by *Staphylococcus* spp. (*S. aureus* and *S. intermedius*), *E. coli*, *Pasteurella multocida* and *Pseudomonas aeruginosa*
- Urinary tract infections caused by *Staphylococcus* spp. (*S. aureus* and *S. intermedius*), *Streptococcus* spp, *Enterobacteriaceae* (*E. coli*, *Proteus* spp., *Klebsiella* spp., *Citrobacter freundii*, *Enterobacter cloacae*) and *Pseudomonas aeruginosa*
- Respiratory tract infections caused by *Pasteurella multocida*, *Enterobacteriaceae* (*E. coli*, *Klebsiella pneumoniae*), *Staphylococcus* spp. (*S. aureus*, *S. intermedius*), *Pseudomonas aeruginosa*, *Bordetella bronchiseptica* and *Streptococcus* spp.

Cases of resistance have been observed in *Streptococcus*.

Strains from dermal infections in cats and dermal and UTI infections in dogs with MIC < 1 µg/ml are sensitive to marbofloxacin (CLSI, 2008) whereas strains with MIC ≥ 4 µg/ml are resistant to marbofloxacin.

Resistance to fluoroquinolones occurs by chromosomal mutation with the following mechanisms: Decrease in bacterial cell wall permeability, expression of genes coding for efflux pump or mutations in genes encoding enzymes responsible for molecule binding. Plasmid-mediated resistance to fluoroquinolones confer only decreased susceptibility of bacteria, however, it can facilitate development of mutations in genes of target enzymes and can be transferred horizontally. Depending on the underlying resistance mechanism cross-resistance to other (fluoro)quinolones and co-resistance to other antimicrobial classes can occur.

Marbofloxacin is not active against anaerobes, yeasts or fungi.

4.3 Pharmacokinetics

After oral administration in dogs at the recommended dose of 2 mg/kg, marbofloxacin is readily absorbed and reaches maximal plasma concentrations of 1.5 µg/ml within 2 hours.

Its bioavailability is close to 100%.

It is weakly bound to plasma proteins (less than 10%), extensively distributed and in most tissues (liver, kidney, skin, lung, bladder, digestive tract) it achieves higher concentrations than in plasma. Marbofloxacin is eliminated slowly (elimination half-life is 14 hours in dogs) predominantly in the active form in urine (2/3) and faeces (1/3).

5. PHARMACEUTICAL PARTICULARS

5.1 Major incompatibilities

Not applicable.

5.2 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 5 years

Shelf life of tablet halves: 4 days

5.3 Special precautions for storage

This veterinary medicinal product does not require any special temperature storage conditions.

Store the blisters in the original container.

If the tablets are divided, the remaining halves should be returned to the blister pocket.

5.4 Nature and composition of immediate packaging

Alu / PA-Alu-PVC blister each of 6 tablets packed in cardboard box.

Pack sizes:

Cardboard box with 6 tablets
Cardboard box with 12 tablets
Cardboard box with 36 tablets
Cardboard box with 72 tablets
Cardboard box with 120 tablets
Cardboard box with 240 tablets

Not all pack sizes may be marketed.

5.5 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

Medicines should not be disposed of via wastewater.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

6. NAME OF THE MARKETING AUTHORISATION HOLDER

Industrial Veterinaria SA

7. MARKETING AUTHORISATION NUMBERS

Vm 36547/5007
Vm 36547/3007

8. DATE OF FIRST AUTHORISATION

20 February 2017

9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS

November 2025

10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCT

Veterinary medicinal product subject to prescription

Find more product information by searching for the 'Product Information Database' on www.gov.uk.

Gavin Hall
Approved: 10 November 2025